Journal
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Volume 45, Issue 2, Pages 366-375Publisher
AMER THORACIC SOC
DOI: 10.1165/rcmb.2010-0156OC
Keywords
DHA; asthma; inflammation; airway hyperresponsiveness; CPI-17
Funding
- Faculte de medecine et des sciences de la sante (FMSS)
- Centre de Recherche Clinique Etienne LeBel (CRC E-LeBel)
- Foundation of the Marine Biotechnology Research Centre
- Natural Sciences and Engineering Council of Canada (NSERC) of Canada
- Bayer
- Canadian Institute of Health Research
- Canadian Cystic Fibrosis Foundation
Ask authors/readers for more resources
The effects of a newly synthesized docosahexaenoic acid (DHA) derivative, CRBM-0244, on lung inflammation and airway hyperresponsiveness were determined in an in vitro model of TNF-alpha-stimulated human bronchi and in an in vivo model of allergic asthma. Mechanical tension measurements revealed that CRBM-0244 prevented bronchial hyperresponsiveness in TNF-alpha-pretreated human bronchi. Moreover, treatment with CRBM-0244 resulted in a decrease in NF-kappa B activation and cyclooxygenase-2 (COX-2) overexpression triggered by TNF-alpha. The inhibition of peroxisome proliferator-activated receptor-gamma with GW9662 abolished the CRBM-0244 mediated anti-inflammatory effects. CRBM-0244 reduced the Ca2+ sensitivity of bronchial smooth muscle through a decrease in the phosphorylation and expression of the PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa (CPI-17). Results also revealed an overexpression of CPI-17 protein in lung biopsies derived from patients with asthma. Furthermore, the presence of specialized enzymes such as 5-lipoxygenase and 15-lipoxygenase in the lung may convert CRBM-0244 into active mediators, leading to the resolution of inflammation. The in vivo anti-inflammatory properties of CRBM-0244 were also investigated in a guinea pig model of allergic asthma. After oral administration of CRBM-0244, airway leukocyte recruitment, airway mucus, ovalbumin-specific IgE, and proinflammatory markers such as TNF-alpha and COX-2 were markedly reduced. Hence, CRBM-0244 treatment prevents airway hyperresponsiveness, Ca2+ hypersensitivity, and the overexpression of CPI-17 in lung tissue. Together, these findings provide key evidence regarding the mode of action of CRBM-0244 in the lung, and point to new therapeutic strategies for modulating inflammation in patients with asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available